North East and North Cumbria
ICS Formulary
 
back
1 Gastro-intestinal system
01-05-03 Cytokine inhibitors

Adalimumab
Formulary

  • Only approved for use in accordance with NICE guidance. 

Link  NICE TA187: Crohn’s disease - infliximab and adalimumab
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis

Red View adult BNF  View SPC online  View childrens BNF  HCD
Golimumab
Formulary
  • Only approved for use in accordance with NICE guidance. 
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis

Red View adult BNF  View SPC online  View childrens BNF  HCD
Infliximab Remicade®, Inflectra®, Remsima®
Formulary
  • Only approved for use in accordance with NICE guidance.
  • Prescribe by brand only.  

 

Link  Infliximab subcutaneous injection (Remsima SC ®) - interim COVID-19 guidance
Link  NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Link  NICE TA187: Crohns disease - infliximab & adalimumab
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Link  NTAG recommends the use of infliximab biosimilars as an option where the originator product (Remicade®) would normally be prescribed

Red View adult BNF  View SPC online  HCD
Risankizumab Skyrizi®
Formulary
  • 150mg/1ml solution for injection (pre-filled devices)
  • Approved for previously treated moderately to severely active Crohn's disease in people 16 years and over in line with NICE
Link  NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease

Red View adult BNF  View SPC online  View childrens BNF  HCD
Ustekinumab Stelara®
Formulary
  • 130 mg concentrate for solution for infusion
  • Approved for previously treated moderately to severely active Crohn’s disease in adults in line with NICE
  • Approved for treating moderately to severely active ulcerative colitis in line with NICE

 

Link  MHRA Drug Safety Update (Jan 2015): Ustekinumab (Stelara): risk of exfoliative dermatitis
Link  NICE TA456 Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Link  NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis

Red View adult BNF  View SPC online  View childrens BNF  HCD
Ozanimod Zeposia®
Formulary
  • Approved for moderately to severely active ulcerative colitis in adults in line with NICE.
Link  NICE TA 828: Ozanimod for treating moderately to severely active ulcerative colitis

Red View adult BNF  View SPC online  View childrens BNF